T-Cure Bioscience

T-Cure Bioscience

Edit info

  • Founded: 2016
  • Location: Sherman Oaks, CA
  • Employee range: 11 - 50
  • Clinical stage: Clin1
  • Therapy area: Renal cell carcinoma
  • Drug types: ONC
  • Lead product: 800 TCR
  • Funding: not disclosed


t-cure.com

linkedin.com

job board


Drug notes:

820 TCR Clin0 multiple cancers; 806 TCR Clin0 solid tumors; 402 TCR RD/Clin0 solid tumors; 821 TCR RD/Clin0 solid tumors; 830 TCR RD/Clin0 solid tumors; therapeutic vaccine RD/Clin0 multiple cancers

About:

T-Cure Bioscience is pioneering T cell receptor (TCR) therapy to find effective and durable cures for human cancers. T cell engineering involves genetically modifying the immune cells to redirect them toward tumors. T-Cure is identifying and isolating high avidity TCRs which specifically recognize intracellular or cell-surface targets in solid tumors. These TCRs can then be introduced into viral vectors and inserted in a patients’ own T cells in an ex vivo setting. T-Cure’s lead program, 800TCR, targets HERV-E, a protein that gets turned on during tumor development. Currently, the program is in clinical stages for patients with renal cell carcinoma.

Jobs:

Post a job


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com